Cost-Effectiveness of Earlier Diagnosis of Fibrotic Interstitial Lung Diseases (Fibrotic ILDs) and Earlier Treatment of Its Progressive Form, Progressive Pulmonary Fibrosis (PPF)

Walters, Seth H.;Soulard, Stephane;Ye, Weicheng;Elsen, Aldo;Froidure, Antoine;et.al.
(2026) Advances in Therapy : the international journal of drug, device and diagnostic research — Vol. 43, n° 7, p. 3134-3147 (2026)

Files

Cost-effectiveness of earlier diagnosis of ILD PPF Mar-06-2026.pdf
  • Open Access
  • Adobe PDF
  • 581.19 KB
Download

Details

Authors
  • Walters, Seth H.
    Author
  • Soulard, Stephane
    Author
  • Ye, Weicheng
    Author
  • Elsen, Aldo
    Author
  • Froidure, Antoine
    Author
Show more
Abstract
Introduction: Early treatment for progressive pulmonary fibrosis (PPF) improves outcomes. However, diagnosis of fibrotic-interstitial lung diseases (fibrotic ILDs), and detection of potentially emergent PPF is delayed on average by 9-12 months. New ILD diagnostic and PPF monitoring strategies are being investigated that aim to allow early treatment to improve patient outcomes.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Walters, S. H., Soulard, S., Ye, W., Elsen, A., Kongnakorn, T., Raj, S. S., Pimple, P., Ferreira, P. G., & Froidure, A. (2026). Cost-Effectiveness of Earlier Diagnosis of Fibrotic Interstitial Lung Diseases (Fibrotic ILDs) and Earlier Treatment of Its Progressive Form, Progressive Pulmonary Fibrosis (PPF). Advances in Therapy : the international journal of drug, device and diagnostic research, 43(7), 3134-3147. https://doi.org/10.1007/s12325-026-03601-8 (Original work published 2026)